(Q57274411)

English

Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Re

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7484829%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7484829%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

author name string

The PPP Project Investigators

1

0 references

language of work or name

0 references

publication date

1 November 1995

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7484829%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

American Journal of Cardiology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7484829%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

76

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7484829%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

899-905

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7484829%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7484829%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

The value of lowering cholesterol after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Should there be a moratorium on the use of cholesterol lowering drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Cholesterol and total mortality: need for larger trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Clinical implications of new drugs for lowering plasma cholesterol concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

The analysis of multiple endpoints in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Cholesterol and mortality. 30 years of follow-up from the Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Cholesterol lowering and mortality: the importance of considering initial level of risk

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Assessing possible hazards of reducing serum cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Pravastatin, lipids, and major coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980259-8

7 January 2021

Identifiers

10.1016/S0002-9149(99)80259-8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7484829%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7484829%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57274411&oldid=1371377235"